Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. - Wikidata - wikimedia - TriplyDB

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

http://www.wikidata.org/entity/Q35776066

about

Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease Development of positron emission tomography β-amyloid plaque imaging agents Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.Future Directions in Imaging Neurodegeneration.Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia Should we disclose amyloid imaging results to cognitively normal individuals?Molecular imaging of Alzheimer disease pathology Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease Emerging β-amyloid pathology and accelerated cortical atrophy.Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Overview and findings from the religious orders study Quantitative multimodal multiparametric imaging in Alzheimer's disease.Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio.Recent advances in neuroimaging biomarkers in geriatric psychiatry.Association of plasma and cortical amyloid beta is modulated by APOE ε4 status CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging.Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.Detection of Aβ plaque deposition in MR images based on pixel feature selection and class information in image level.Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease.Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.Harnessing the immune system for treatment and detection of tau pathology.Amyloid imaging in Alzheimer's disease: a literature review.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Genetic epistasis regulates amyloid deposition in resilient aging.The emerging role of PET imaging in dementia.Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation.A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor.Amyloid imaging in depression: a predictor of Alzheimer's disease?Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.

P2860

Q26783306-8E15897D-0701-4600-A98C-97D83227C72B Q27012742-7E53C6C9-29E8-41F1-99F5-0E9CB72E7743 Q30996799-C8F13ADF-0CBA-4237-A904-D598A46D6DF9 Q31162702-2B6AB9D8-D35E-4911-88A2-6F5F03645A75 Q33727909-C637A50C-ECC3-4957-8ABC-B8E4C3E7CCF0 Q34286140-9A86C6EE-1299-445D-B51B-95D6ED86E1B2 Q34651135-97624D44-4434-4EB8-B238-5D99A2D5005E Q35284971-D0276683-7AD7-4C6F-A3CA-D7ADBFE617BA Q35542164-689CE854-6024-4549-BD0B-3B29DEA0521E Q35894473-E6736CFF-C7F2-4956-B23D-8B022184574C Q35949385-FA609DE9-6CD5-4E86-A887-4D5CBA5C6281 Q36018654-92C9B625-A95F-4937-9E15-B340477FD51B Q36121377-55C4AE0F-A215-4EFE-BD27-1B2339E34922 Q36130996-9AE04178-E07F-4AAC-A2E2-5A82F306F8BE Q36164757-17A884CA-7EBB-46F4-A1D5-BF0A705DE629 Q36218847-271385CF-9985-41FC-BF85-6F55674C1014 Q36267484-38FDBECC-7E4A-467E-B4A7-04F49813AF10 Q36885496-B5F57E6E-6727-4599-9645-ADBE38D98D2C Q37112462-8759DB6B-CED0-41DE-80C0-012F2B5C74AB Q37129599-48F53705-4C19-4231-A2EC-835B45227BA2 Q37141423-F7C6BF77-C655-435A-8F75-E8810909A108 Q37148091-CEFD76A5-493E-447D-A2A2-1F8C364A4BC4 Q37260549-AD0C9E84-4E11-4680-B0BF-BFCDAEAE32FD Q37386143-571432A1-B081-4DD2-A9C0-C0A42CCF38DF Q37730221-D7DF8910-6C0A-4679-9C87-8A13AE2BC480 Q38194049-C9EFD947-1225-4BB8-8D07-AF0E383015C0 Q38250091-35037659-1E6E-40C6-AF65-8D8C9086AA34 Q38830945-3A4AD28D-069A-4045-BA8C-596FA12D3FB2 Q38891562-214C3CBF-1E5E-40DA-B473-46FF635253BE Q42701971-325C3BC0-6D1D-45BA-8C5C-A03EB37E1E5B Q45732943-A9EECBA8-86B8-4949-99BA-A12BE4D010CF Q46427093-FB3806C4-2150-430D-8CEA-94E5C89588D1 Q47549851-96284BFD-A443-483C-B078-4125478C4A59 Q47768829-45C8BD7B-D80E-4ED6-A731-9669C0847BAC Q47833026-C7991DEB-6CE2-479A-885D-F72E07F1D247 Q48339409-3FEA04E8-62D0-4677-8B59-3619B632B7BF Q48609636-95EC750B-224B-497A-95E9-7E5DD0E2CAAD Q50239485-24DCC84F-0AE6-40AC-9F99-0AC178490B35 Q51481172-0F6E497A-84FC-411B-888A-0FDCCE193FFA Q53172274-E2F6C617-CBED-46C0-9F6F-676CF0A3E1C0

P2860

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

http://www.wikidata.org/entity/Q35776066

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@ast

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@en

type

label

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@ast

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@en

prefLabel

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@ast

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@en

P1433

Q35776066-0D295EA8-3487-4A32-9C2F-0159A5CB8235

P1476

Q35776066-B63DDBDD-3C1E-480A-BA0D-AAF1103741F4

P2093

Q35776066-0AD5F416-C1C2-40E2-961B-44BF790DBC72

Q35776066-1D09038B-4F2C-4F3C-89B7-405C66FE0F61

Q35776066-2277D2D5-8924-4009-AAA7-0EB87AC02AFE

Q35776066-2D886E58-66BA-49A3-9168-34A467CB1E59

Q35776066-7AB02C78-0F22-47A2-A4A2-4CC969DFD757

Q35776066-8AFC4D69-9F3E-412B-915C-E30CC3F78249

Q35776066-B90B11C9-2A9B-42EA-9E6C-762ECE860F12

Q35776066-D2405943-F404-4341-9712-AA4762024F4F

Q35776066-FB4C906E-49AE-4A27-8372-05F726FA7613

P2860

Q35776066-015768A2-1BBD-49A4-AD1D-E58BA852BE8D

Q35776066-04C2B0C0-5162-4E0B-A04F-3892D24FFE35

Q35776066-0AA10E92-449F-4D48-B6CA-FC5D49D137F2

Q35776066-1C71583D-A4D2-40D1-BD73-B16053F245A5

Q35776066-200E0737-5955-4BC9-BC66-B09FD3FA25A9

Q35776066-22593F32-D721-4E26-983F-11533A738CE4

Q35776066-25BE7F13-DD74-4D63-BC57-A8CC5FD236C1

Q35776066-4541C284-FE61-4E57-991A-1E720D2F936A

Q35776066-49621EE3-E5B4-4F4D-8ED4-F91C523DD480

Q35776066-4AC1F1C6-8F83-4FBC-8878-CFF8F7679300

P304

Q35776066-409277BF-060F-430D-8E84-A6782E769440

P31

Q35776066-65BDBE94-8DE6-449D-B628-F3C3AFE9AE73

P356

Q35776066-6A919637-F195-41B5-BD80-EE913F4F32CF

P407

Q35776066-F386BB87-BAFC-476F-975F-4825386974B0

P433

Q35776066-32E4A2AF-2FDC-4BF0-987C-A2246A0EE3BB

P478

Q35776066-7CB3FCD1-61B7-4DFD-B5C1-B24A80189FA1

P50

Q35776066-D966B8C4-6FD4-43F5-944F-45BDA884B5CB

Q35776066-EDFA4043-DED5-4EAF-ADC3-459B04E3A850

P577

Q35776066-0E4A2D28-A095-4B79-91B9-861E4CB9E18E

P698

Q35776066-ED9784FC-98B2-42A0-9F81-BC27F4755753

P921

Q35776066-B22250B0-0239-4018-B9F7-C828B2344EE2

P932

Q35776066-07A8DA4D-E55F-4B5C-9772-F924BCE4B795

P356

WAD.0B013E31821300BC

P1433

Alzheimer Disease and Associated Disorders

P1476

Correlation of amyloid PET lig ...... on in postmortem brain tissue.

@en

P2093

Barry J Bedell

http://www.w3.org/2001/XMLSchema#string

Christopher M Clark

http://www.w3.org/2001/XMLSchema#string

Daniel M Skovronsky

http://www.w3.org/2001/XMLSchema#string

Franz Hefti

http://www.w3.org/2001/XMLSchema#string

Hank F Kung

http://www.w3.org/2001/XMLSchema#string

Julie A Schneider

http://www.w3.org/2001/XMLSchema#string

Michael J Krautkramer

http://www.w3.org/2001/XMLSchema#string

Seok Rye Choi

http://www.w3.org/2001/XMLSchema#string

Simone P Zehntner

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer's Disease

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases

Protein misfolding, functional amyloid, and human disease

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease.

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.

P304

8-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/WAD.0B013E31821300BC

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

David A Bennett

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22354138

http://www.w3.org/2001/XMLSchema#string

P921

Florbetapir (18F)

P932

3286131

http://www.w3.org/2001/XMLSchema#string